caa a22 4500 46907406X CHVBK 20180323132930.0 cr unu---uuuuu 170328e19920301xx s 000 0 eng 10.1007/BF01741860 doi (NATIONALLICENCE)springer-10.1007/BF01741860 Influence of antibody protein dose on therapeutic efficacy of radioiodinated antibodies in nude mice bearing GW-39 human tumor [Elektronische Daten] [Otto Boerman, Robert Sharkey, George Wong, Rosalyn Blumenthal, Rosarito Aninipot, David Goldenberg] Summary: The biodistributions of three131I-labeled murine monoclonal antibodies, NP-4 and Immu-14 anti-(carcinoembryonic antigen), and Mu-9 anti-(colon-specific antigen p), were determined at antibody protein doses varying from 1 µg to 1000 µg in nude mice with small (0.1-0.4 g) GW-39 human colonic cancer xenografts. For each antibody, the percentage of the injected dose per gram of tumor and tumor/nontumor ratios were constant over a wide protein dose range. However, at high protein doses (above 100 µg for NP-4 and Immu-14) the percentage of the injected dose per gram of tumor and tumor/nontumor ratios decreased. Assuming that the uptake of a control anti-(α-fetoprotein) antibody represents the amount of antibody that accumulates in the tumor nonspecifically (i.e., antigen-independently), it could be shown that for each antibody the amount of antibody protein that accumulates in the tumor specifically, increases linearly with the protein dose, reaching a plateau level at the highest doses tested. The growth inhibition of GW-39 tumor transplants in nude mice treated with131I-labeled antibody at either low or high antibody protein dose was compared. These experiments indicated that, in this experimental model, enhanced antibody protein dose may decrease the therapeutic efficacy of radioiodinated antibodies. It is suggested that heterogeneous distribution at low protein dose, with intense localization around the blood vessels, may enhance the tumoricidal effect of radioantibodies. Springer-Verlag, 1992 Radioantibodies nationallicence Microdistribution nationallicence Radioimmunotherapy nationallicence Boerman Otto Garden State Cancer Center and Center for Molecular Medicine and Immunology, 1 Bruce Street, 07 103, Newark, NJ, USA aut Sharkey Robert Garden State Cancer Center and Center for Molecular Medicine and Immunology, 1 Bruce Street, 07 103, Newark, NJ, USA aut Wong George Garden State Cancer Center and Center for Molecular Medicine and Immunology, 1 Bruce Street, 07 103, Newark, NJ, USA aut Blumenthal Rosalyn Garden State Cancer Center and Center for Molecular Medicine and Immunology, 1 Bruce Street, 07 103, Newark, NJ, USA aut Aninipot Rosarito Garden State Cancer Center and Center for Molecular Medicine and Immunology, 1 Bruce Street, 07 103, Newark, NJ, USA aut Goldenberg David Garden State Cancer Center and Center for Molecular Medicine and Immunology, 1 Bruce Street, 07 103, Newark, NJ, USA aut Cancer Immunology, Immunotherapy Springer-Verlag 35/2(1992-03-01), 127-134 0340-7004 35:2<127 1992 35 262 https://doi.org/10.1007/BF01741860 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01741860 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Boerman Otto Garden State Cancer Center and Center for Molecular Medicine and Immunology, 1 Bruce Street, 07 103, Newark, NJ, USA aut NATIONALLICENCE 700 1- Sharkey Robert Garden State Cancer Center and Center for Molecular Medicine and Immunology, 1 Bruce Street, 07 103, Newark, NJ, USA aut NATIONALLICENCE 700 1- Wong George Garden State Cancer Center and Center for Molecular Medicine and Immunology, 1 Bruce Street, 07 103, Newark, NJ, USA aut NATIONALLICENCE 700 1- Blumenthal Rosalyn Garden State Cancer Center and Center for Molecular Medicine and Immunology, 1 Bruce Street, 07 103, Newark, NJ, USA aut NATIONALLICENCE 700 1- Aninipot Rosarito Garden State Cancer Center and Center for Molecular Medicine and Immunology, 1 Bruce Street, 07 103, Newark, NJ, USA aut NATIONALLICENCE 700 1- Goldenberg David Garden State Cancer Center and Center for Molecular Medicine and Immunology, 1 Bruce Street, 07 103, Newark, NJ, USA aut NATIONALLICENCE 773 0- Cancer Immunology, Immunotherapy Springer-Verlag 35/2(1992-03-01), 127-134 0340-7004 35:2<127 1992 35 262 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer